News Vanda bats away unwanted Cycle, Future Pak takeover bids Vanda Pharmaceuticals' board is unimpressed with takeover offers from both Cycle Pharma and Future Pak, saying they both “substantially undervalue” the company.
News Cycle Pharma makes $466m takeover bid for Vanda UK group Cycle Pharma has made an unsolicited takeover bid to buy Vanda Pharma of the US, which is already fending off an overture from Future Pak.
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends